News and Events from NHTherapeutics

January 19th, 2017

NHTherapeutics is granted Orphan Drug Designation by the European Medicines Agency

http://finance.yahoo.com/news/nhtherapeutics-announces-european-commission-grants-131400540.html

December 8th, 2015

John Kaiser joins NHTherapeutics Board of Directors

http://finance.yahoo.com/news/john-kaiser-joins-nhtherapeutics-board-131000838.html

September 8th, 2015

NHTherapeutics has begun research and development of buccal leuprolide and made the first tranche of payments to Generex, its formulation partner.

http://finance.yahoo.com/news/generex-announces-commencement-buccal-leuprolide-133000333.html

May 26th, 2015

NHTherapeutics has entered into a Memorandum of Understanding with Generex pursuant to which the companies will co-develop a formulation for the delivery of Leuprolide into the human body via the buccal mucosa using the Generex proprietary RapidMist™ buccal drug delivery system.

http://finance.yahoo.com/news/generex-announces-collaboration-nhtherapeutics-utilize-133000366.html